[1] Bladder cancer is usually stratified into two broad categories: papillary superficial and solid invasive tumors. Superficial tumors are the most frequent of all newly diagnosed bladder cancers ...

Some patients with low-grade Ta nonmuscle-invasive bladder cancer (LG Ta NMIBC) can experience recurrence after many years.

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

Conclusions: High-grade noninvasive papillary bladder tumours are associated ... observed particularly in high grade urothelial bladder cancer clearly warrant subsequent studies on the potential ...

for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary ...

for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. The drug is combined with the BCG vaccine, mainly used against ...

The drugmaker is seeking to have the therapy approved for the treatment of Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with or ...

J&J on Wednesday said the application covers TAR-200 in Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

The J&J filing seeks the FDA’s nod for TAR-200 as a single agent to treat patients with BCG-unresponsive, high-risk NMIBC with carcinoma in-situ (CIS), with or without papillary tumors.

released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle ...